trending Market Intelligence /marketintelligence/en/news-insights/trending/AfwYRUYbO6CEftrg6ZmpGg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Private equity firm Afinum buys majority stake in Swiss biotech evitria

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Private equity firm Afinum buys majority stake in Swiss biotech evitria

Private equity firm Afinum Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in Swiss biotechnology company evitria AG.

Evitria provides custom antibodies to pharmaceutical and biotech companies for research purposes.

Afinum Achte Beteiligungsgesellschaft mbH & Co. KG, advised by Afinum Management GmbH, acts as lead investor and majority owner, and jointly invests with SHS V Medtech Investments GmbH & Co. KG and management into evitria.